Three Right Elbows

Three things happened in Florida this week that will not appear on any box score.

Hurston Waldrep, the 57th overall pick in the 2023 draft, learned that the loose bodies removed from his right elbow in February were prologue. The ligament tore. Tommy John surgery will follow. He is twenty-four years old and will not pitch competitively until 2028 at the earliest.

Spencer Schwellenbach learned that the bone spurs removed from the same elbow that fractured in June 2025 were treating a symptom. The fracture returned. Another surgery. He is twenty-six, and his career — a 3.23 ERA across 38 starts, 235 strikeouts, the kind of early résumé that lets a pitching coordinator sleep at night — has now been interrupted twice by the same bone in the same arm.

And Spencer Strider, whose right elbow was inflamed on June 12 and has not improved since, is there too. Walt Weiss was asked about his status. "Time is running out," the manager said. The sentence did not require elaboration.

Three right-handed pitchers. Three right elbows. All of them at the Braves' Spring Training complex while the team they were supposed to carry into October is 79-55 and winning its sixth straight.

Twenty-five days ago, in this space, I wrote about seven names behind Chris Sale for the October rotation and found none of them proven. Schwellenbach, at that point, was "three side sessions from a rehab start."

I was wrong. The side sessions became a surgical consultation. The rehab start became a second fracture. And the seven names behind Sale are now four: Sale, Tyler Mahle, Bryce Elder, Grant Holmes. That is the October rotation. There is no longer a scenario where the young arms come back. The variable has resolved.

Weiss framed it with the precision of a man who has watched bodies overrule organizational plans before: "The guys were going through their throwing progressions. At some point, if things aren't right, they're going to flare up again. That's simply what happened with both guys."

If things aren't right, they're going to flare up again. That is not a medical update. It is a philosophy of pitching development compressed into twelve words. The body has veto power over the spreadsheet, and this week it exercised that power three times simultaneously.

And yet.

The Braves' 99.9 percent playoff probability has not moved. The NL East lead has not contracted. The rotation behind Sale — Mahle's 1.52 ERA since the deadline trade, Elder's post-break renaissance from a 7.70 mid-July ERA to consistent quality starts, Holmes's 2.93 ERA over his last six outings — is constructed from different materials than the young arms now in surgery, but it is constructed. These are not placeholders. They are the answer.

The number buried beneath the surgery announcements is 0.56. That is Robert Suarez's ERA through 31 appearances before his own right elbow sent him to the injured list on June 19. He has been throwing pain-free on flat ground from 120 feet. The mound test comes next week. If the arm cooperates — and that conditional is load-bearing — Suarez in September transforms the bullpen for October in ways a rotation addition could not. With Raisel Iglesias posting a 5.79 ERA since June, the Braves' high-leverage picture needed Suarez before these surgeries were announced. It needs him more now.

The Braves have always been defined by pitching. Maddux, Glavine, Smoltz — seven combined Cy Young Awards from three arms that stayed healthy when it mattered. The institutional expectation is that the pipeline provides. It still will. Waldrep will return. Schwellenbach may return. Strider's story is unfinished.

But not this October. This October belongs to a thirty-seven-year-old ace, a deadline rental, a bounce-back story, and a breakout candidate. Four arms, none of them the ones the franchise planned on. The body vetoed the plan. The Braves built another one.